Health
Moderna launches COVID-19 vaccine booster study to address new variants – PMLiVE
First participants receive company’s modified vaccine candidates
Moderna has begun giving booster doses of its COVID-19 vaccine to trial participants as part of an amendment to a phase 2 clinical study.
The phase 2 trial amendment has enrolled 60 participants who have already received Moderna’s original mRNA-1273 vaccine. They will receive a single booster dose of a modified candidate addressing the B.1.351 variant or a multivalent booster candidate.
The variant-specific booster candidate – mRNA-1273.351 – encodes for the spike protein of the SARS-CoV-2 variant…
-
Noosa News4 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
General19 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News5 hours agoMotorcyclist dies in crash with truck
-
Noosa News20 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial